Literature DB >> 1671670

Increased susceptibility of IFN-gamma-treated neuroblastoma cells to lysis by lymphokine-activated killer cells: participation of ICAM-1 induction on target cells.

H Naganuma1, R Kiessling, M Patarroyo, M Hansson, R Handgretinger, A Grönberg.   

Abstract

We have investigated the effect of interferon-gamma (IFN-gamma) treatment of neuroblastoma cells on the susceptibility to lysis by lymphokine-activated killer (LAK) cells and examined the participation of cell-adhesion molecules on the target cells in LAK cell lysis. Untreated neuroblastoma cells expressed lymphocyte-function-associated antigen 3 (LFA-3) and neural-cell-adhesion molecule (NCAM), but did not express MHC-class-I, MHC-class-II, or intercellular-adhesion molecule I (ICAM-I). IFN-gamma treatment of neuroblastoma cells induced the expression of MHC-class-I and ICAM-I antigens, but did not affect the expression of MHC-class-II, LFA-3, and NCAM. This was accompanied by an increased susceptibility to lysis by LAK cells. Anti-ICAM-I antibody inhibited partially the increased sensitivity of IFN-gamma-treated neuroblastoma cells to LAK cell lysis, and blocked completely the increase in binding of LAK cells observed after IFN-gamma treatment of the target cells. These results suggest that the increased LAK sensitivity of IFN-gamma-treated neuroblastoma cells is partially attributable to the induction of ICAM-I on neuroblastoma cells and indicate that post-binding events also play a role in the increased sensitivity to LAK cell lysis observed after IFN-gamma treatment.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1671670     DOI: 10.1002/ijc.2910470410

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  17 in total

1.  Natural killer cell-produced IFN-γ and TNF-α induce target cell cytolysis through up-regulation of ICAM-1.

Authors:  Ruipeng Wang; Jessica J Jaw; Nicole C Stutzman; Zhongcheng Zou; Peter D Sun
Journal:  J Leukoc Biol       Date:  2011-11-01       Impact factor: 4.962

2.  Potentiation of long-term-cultured lymphokine-activated killer cell cytotoxicity against small-cell lung carcinoma by anti-CD3 x anti-(tumor-associated antigen) bispecific antibody.

Authors:  A Azuma; H Yagita; K Okumura; S Kudoh; H Niitani
Journal:  Cancer Immunol Immunother       Date:  1994-05       Impact factor: 6.968

3.  Role of intercellular adhesion molecule-1 (ICAM-1) and lymphocyte function-associated antigen-1 (LFA-1) in peripheral blood mononuclear cell activation by human renal carcinoma cells.

Authors:  A B Hansen; C B Andersen
Journal:  Urol Res       Date:  1994

4.  Interferon-gamma-induced increased sensitivity of HER2/neu-overexpressing tumor cells to lymphokine-activated killer cell lysis: importance of ICAM-1 in binding and post-binding events.

Authors:  C Fady; A Gardner; J F Gera; A Lichtenstein
Journal:  Cancer Immunol Immunother       Date:  1993-10       Impact factor: 6.968

5.  Association between ICAM-1 expression and metastatic capacity of murine B-cell hybridomas.

Authors:  R G Hawley; M H Wang; A Z Fong; T S Hawley
Journal:  Clin Exp Metastasis       Date:  1993-03       Impact factor: 5.150

6.  Cytokine regulation of cell-to-cell interactions in lymphokine-activated killer cell cytotoxicity in vitro.

Authors:  T Takahashi; H Ishikura; K Iwai; C Takahashi; H Kato; T Tanabe; T Yoshiki
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

7.  Medullary carcinoma is associated with expression of intercellular adhesion molecule-1. Implication to its morphology and its clinical behavior.

Authors:  S S Bacus; C R Zelnick; D M Chin; Y Yarden; D B Kaminsky; J Bennington; D Wen; J N Marcus; D L Page
Journal:  Am J Pathol       Date:  1994-12       Impact factor: 4.307

8.  Effect of interferon gamma on the sensitivity of bovine-papilloma-virus(BPV1)-transformed cell lines to cell-mediated cytotoxicity.

Authors:  A Laatikainen; L Schultz-Suhonen; R Mäntyjärvi
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

9.  Diverse effect of cytokine treatment of tumor cells on specific versus non-specific cytotoxicity.

Authors:  H Naganuma; E Halapi; G Masucci; M Hansson; P Wersäll; C Hising; S Venkateswaran; H Mellstedt; R Kiessling
Journal:  Med Oncol Tumor Pharmacother       Date:  1992

10.  Decrease in lymphokine-activated killer sensitivity of a human renal-cell carcinoma cell line after cytokine treatment.

Authors:  M Yanase; T Tsukamoto; Y Kumamoto; K Kato; Y Hashimoto
Journal:  Cancer Immunol Immunother       Date:  1994-07       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.